Erasca rises on partnership with Tango to test new cancer drug combo

Tango Therapeutics

05/03/2026 17:57

** Shares of drug developer Erasca ERAS.O rise 1.06% to $15.28

** Co says it will partner with Tango Therapeutics TNGX.O to test combo of two experimental drugs for pancreatic and lung cancers

** Says the study will enroll patients whose tumors have RAS mutations and an MTAP gene loss, a combo that limits treatment options

** ERAS says its drug ERAS‑0015 has shown early signs of shrinking tumors at low doses; TNGX will provide vopimetostat, which blocks a protein called PRMT5

** Companies plan an early‑stage trial, with each keeping rights to its own drug; deal is non‑exclusive

** Shares of drug developer Tango Therapeutics TNGX.O rise 23.4% to $15.26

** Shares of ERAS up ~48%, TNGX up ~187% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))